Home › Companies › AKERO THERAPEUTICS INC. › 2024-2025
Download data (CSV): ballot items · votes by manager · column guide.
Compiled from SEC Form N-PX filings and AKERO THERAPEUTICS INC.’s Form 8-K, filed June 4, 2025 (Item 5.07 on EDGAR). Page generated November 20, 2026.
Meeting of June 3, 2025: 4 items on AKERO THERAPEUTICS INC.’s Form 8-K, filed June 4, 2025: 3 passed (calculated) · 1 plurality election.
Significant dissent: 2 directors (54.9%, 24.8% against).
Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided
Explore AKERO THERAPEUTICS INC. in the interactive database Compare manager voting policies
These tallies are AKERO THERAPEUTICS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 4, 2025 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Judy Chou, Ph.D. | 46,654,444 | -- | -- | 15,405,899 | 5,333,604 | 75% | Passed (calculated) | — |
| Elect Director: Tomas Heyman | 28,017,151 | -- | -- | 34,043,192 | 5,333,604 | 45.1% | Plurality election | — |
| Company's stockholders approved to ratify the appointment of Deloitte & Touche LLP in Proposal 2. | 67,325,603 | 38,564 | 29,780 | -- | 0 | 99.9% | Passed (calculated) | — |
| Company's stockholders approved, by non-binding advisory vote, the compensation of the Company's named executive officers in Proposal 3. | 60,698,263 | 1,199,541 | 162,539 | -- | 5,333,604 | 98% | Passed (calculated) | — |
Source: AKERO THERAPEUTICS INC., Form 8-K, filed with the SEC on June 4, 2025 — read the filing on EDGAR.
See voting trends for Health Care companies, 2024-2025: shareholder support by sector and by company size.
258 asset managers disclosed a vote on at least one AKERO THERAPEUTICS INC. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report.
Combines 6 wordings of this item as funds reported it.
75% Majority: yes · of votes cast
Description as filed by funds: To elect two class III directors, Judy Chou, Ph.D. and Tomas Heyman, to our board of directors, to serve until the 2028 Annual Meeting of stockholders and until her or his successor has been duly elected and qualified, or until her or his earlier death, resignation or removal: Judy Chou, Ph.D.
AKERO THERAPEUTICS INC.’s own tally for this item (“Elect Director: Judy Chou, Ph.D.”): 46,654,444 for, 15,405,899 withheld, per its Form 8-K filed June 4, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts using a plurality of the votes cast, the standard stated in the company’s proxy statement: votes for exceeded votes against.
Support: 75% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 80 asset managers below reported 18,399,914 for, 6,798,202 withheld, 135,430 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 7,781,005 | 0 | 0 | 0 | For |
| T. Rowe Price | 0 | 0 | 0 | 3,360,888 | Withhold |
| Fidelity | 2,614,174 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 2,139,467 | 0 | 0 | 0 | For |
| BlackRock | 1,750,114 | 0 | 0 | 0 | For |
| State Street | 974,743 | 0 | 0 | 1,097 | For |
| ACAP Strategic Fund | 0 | 0 | 0 | 743,040 | Withhold |
| Charles Schwab | 588,455 | 0 | 0 | 0 | For |
| TIAA | 415,114 | 0 | 0 | 0 | For |
| AllianceBernstein | 0 | 0 | 0 | 406,747 | Withhold |
| Aberdeen | 0 | 0 | 0 | 406,700 | Withhold |
| Principal | 159 | 0 | 0 | 304,719 | Withhold |
| Equitable | 118,844 | 0 | 0 | 185,900 | Mixed |
| ALGER FUNDS | 0 | 0 | 0 | 302,068 | Withhold |
| Loomis Sayles | 280,157 | 0 | 0 | 0 | For |
| AB DISCOVERY GROWTH FUND, INC. | 0 | 0 | 0 | 239,130 | Withhold |
| Hartford | 229,255 | 0 | 0 | 0 | For |
| Advantage Advisers Xanthus Fund, L.L.C. | 0 | 0 | 0 | 211,967 | Withhold |
| MUTUAL FUND SERIES TRUST | 200,000 | 0 | 0 | 0 | For |
| Yiheng Capital Management, L.P. | 176,260 | 0 | 0 | 0 | For |
| Brighthouse | 76,631 | 0 | 0 | 82,424 | Mixed |
| Columbia Threadneedle | 153,335 | 0 | 0 | 0 | For |
| JPMorgan | 135,429 | 0 | 0 | 0 | For |
| Dimensional | 0 | 0 | 0 | 135,214 | Withhold |
| QUANTITATIVE MASTER SERIES LLC | 126,846 | 0 | 0 | 0 | For |
Showing the 25 largest of 80 asset managers. All 80 are in the interactive database (link above).
Combines 6 wordings of this item as funds reported it.
45.1% Plurality election · of votes cast
Description as filed by funds: To elect two class III directors, Judy Chou, Ph.D. and Tomas Heyman, to our board of directors, to serve until the 2028 Annual Meeting of stockholders and until her or his successor has been duly elected and qualified, or until her or his earlier death, resignation or removal: Tomas Heyman
AKERO THERAPEUTICS INC.’s own tally for this item (“Elect Director: Tomas Heyman”): 28,017,151 for, 34,043,192 withheld, per its Form 8-K filed June 4, 2025 (Item 5.07). This is a for/withhold election, which is decided by plurality: a nominee does not need a majority of the votes cast to be elected, so no passed or failed outcome is stated here.
Outcome: Plurality election — The company’s filing reports the vote counts but does not state the outcome; this is an election decided by plurality, so a nominee does not need a majority of the votes cast and no passed or failed outcome is calculated.
Support: 45.1% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 80 asset managers below reported 7,997,110 for, 15,092,151 withheld, 2,244,285 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 4,122,882 | 0 | 0 | 3,658,123 | Mixed |
| T. Rowe Price | 0 | 0 | 0 | 3,360,888 | Withhold |
| Fidelity | 1,011,588 | 0 | 0 | 1,602,586 | Mixed |
| JANUS INVESTMENT FUND | 2,139,467 | 0 | 0 | 0 | For |
| BlackRock | 109,966 | 0 | 1,640,148 | 0 | Mixed |
| State Street | 2,270 | 0 | 0 | 973,570 | Withhold |
| ACAP Strategic Fund | 0 | 0 | 0 | 743,040 | Withhold |
| Charles Schwab | 0 | 0 | 0 | 588,455 | Withhold |
| TIAA | 0 | 0 | 0 | 415,114 | Withhold |
| AllianceBernstein | 0 | 0 | 0 | 406,747 | Withhold |
| Aberdeen | 0 | 0 | 0 | 406,700 | Withhold |
| Principal | 0 | 0 | 0 | 304,878 | Withhold |
| Equitable | 0 | 0 | 0 | 304,744 | Withhold |
| ALGER FUNDS | 0 | 0 | 0 | 302,068 | Withhold |
| Loomis Sayles | 0 | 0 | 280,157 | 0 | Abstain |
| AB DISCOVERY GROWTH FUND, INC. | 0 | 0 | 0 | 239,130 | Withhold |
| Hartford | 0 | 0 | 0 | 229,255 | Withhold |
| Advantage Advisers Xanthus Fund, L.L.C. | 0 | 0 | 0 | 211,967 | Withhold |
| MUTUAL FUND SERIES TRUST | 200,000 | 0 | 0 | 0 | For |
| Yiheng Capital Management, L.P. | 176,260 | 0 | 0 | 0 | For |
| Brighthouse | 8,019 | 0 | 0 | 151,036 | Mixed |
| Columbia Threadneedle | 0 | 0 | 0 | 153,335 | Withhold |
| JPMorgan | 135,429 | 0 | 0 | 0 | For |
| Dimensional | 0 | 0 | 0 | 135,214 | Withhold |
| QUANTITATIVE MASTER SERIES LLC | 0 | 0 | 126,846 | 0 | Abstain |
Showing the 25 largest of 80 asset managers. All 80 are in the interactive database (link above).
Combines 11 wordings of this item as funds reported it.
98% Majority: yes · of votes cast
Prior year: 95.4% for (June 7, 2024 meeting) ▲ 2.7 pts
Description as filed by funds: To consider and act upon a non- binding, advisory vote to approve the compensation of our named executive officers.
AKERO THERAPEUTICS INC.’s own tally for this item (“The Company's stockholders approved, by non-binding advisory vote, the compensation of the Company's named executive officers in Proposal 3.”): 60,698,263 for, 1,199,541 against, per its Form 8-K filed June 4, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 98% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 7,780,384 | 621 | 0 | 0 | For |
| T. Rowe Price | 3,360,888 | 0 | 0 | 0 | For |
| Fidelity | 2,614,174 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 2,139,467 | 0 | 0 | 0 | For |
| BlackRock | 1,750,114 | 0 | 0 | 0 | For |
| State Street | 975,840 | 0 | 0 | 0 | For |
| ACAP Strategic Fund | 743,040 | 0 | 0 | 0 | For |
| Charles Schwab | 588,455 | 0 | 0 | 0 | For |
| TIAA | 415,114 | 0 | 0 | 0 | For |
| AllianceBernstein | 406,747 | 0 | 0 | 0 | For |
| Aberdeen | 406,700 | 0 | 0 | 0 | For |
| Principal | 304,878 | 0 | 0 | 0 | For |
| Equitable | 304,744 | 0 | 0 | 0 | For |
| ALGER FUNDS | 302,068 | 0 | 0 | 0 | For |
| Loomis Sayles | 280,157 | 0 | 0 | 0 | For |
| AB DISCOVERY GROWTH FUND, INC. | 239,130 | 0 | 0 | 0 | For |
| Hartford | 229,255 | 0 | 0 | 0 | For |
| Advantage Advisers Xanthus Fund, L.L.C. | 211,967 | 0 | 0 | 0 | For |
| MUTUAL FUND SERIES TRUST | 200,000 | 0 | 0 | 0 | For |
| Brighthouse | 159,055 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 153,335 | 0 | 0 | 0 | For |
| Simplify Exchange Traded Funds | 0 | 0 | 145,609 | 0 | Abstain |
| JPMorgan | 135,429 | 0 | 0 | 0 | For |
| Dimensional | 135,214 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 126,846 | 0 | 0 | 0 | For |
Fund voting reports, all 80 managers: 25,126,260 for, 22,263 against, 154,372 abstained. Showing the 25 largest; every one is in the interactive database (link above).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| RTW INVESTMENTS, LP | 7,419,340 | 0 | 0 | 0 | For |
| Janus Henderson | 6,535,723 | 0 | 0 | 0 | For |
| Wellington | 5,388,995 | 0 | 0 | 0 | For |
| T. Rowe Price | 4,459,375 | 0 | 0 | 0 | For |
| BlackRock | 2,445,355 | 0 | 0 | 0 | For |
| State Street | 2,401,865 | 0 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 1,757,957 | 0 | 0 | 0 | For |
| MARSHALL WACE, LLP | 1,693,805 | 0 | 0 | 0 | For |
| Deep Track Capital, LP | 1,407,806 | 0 | 0 | 0 | For |
| AllianceBernstein | 1,160,904 | 0 | 0 | 0 | For |
| Fidelity | 1,008,442 | 0 | 0 | 0 | For |
| Logos Global Management LP | 949,655 | 0 | 0 | 0 | For |
| Redmile Group, LLC | 849,715 | 0 | 0 | 0 | For |
| Point72 | 775,454 | 0 | 0 | 0 | For |
| PERCEPTIVE ADVISORS LLC | 673,795 | 0 | 0 | 0 | For |
| Rock Springs Capital Management LP | 669,147 | 0 | 0 | 0 | For |
| PICTET ASSET MANAGEMENT SA | 616,469 | 0 | 0 | 0 | For |
| Charles Schwab | 595,133 | 0 | 0 | 0 | For |
| ALKEON CAPITAL MANAGEMENT LLC | 567,308 | 0 | 0 | 0 | For |
| Woodline Partners LP | 505,974 | 0 | 0 | 0 | For |
| Northern Trust | 496,897 | 0 | 0 | 0 | For |
| Loomis Sayles | 474,986 | 0 | 0 | 0 | For |
| Nuveen | 420,847 | 0 | 0 | 0 | For |
| SILVERARC CAPITAL MANAGEMENT, LLC | 409,776 | 0 | 0 | 0 | For |
| Aberdeen | 406,700 | 0 | 0 | 0 | For |
Institutional-manager reports, all 199 managers: 49,662,535 for, 458,560 against, 20 not voted. Showing the 25 largest; every one is in the interactive database (link above).
99.9% Majority: yes · of votes cast
Description as filed by funds: TO RATIFY THE APPOINTMENT OF DELOITTE & TOUCHE LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2025.
AKERO THERAPEUTICS INC.’s own tally for this item (“The Company's stockholders approved to ratify the appointment of Deloitte & Touche LLP in Proposal 2.”): 67,325,603 for, 38,564 against, per its Form 8-K filed June 4, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 80 asset managers below reported 25,323,949 for, 834 against, 8,763 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 7,781,005 | 0 | 0 | 0 | For |
| T. Rowe Price | 3,360,888 | 0 | 0 | 0 | For |
| Fidelity | 2,614,174 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 2,139,467 | 0 | 0 | 0 | For |
| BlackRock | 1,750,114 | 0 | 0 | 0 | For |
| State Street | 975,840 | 0 | 0 | 0 | For |
| ACAP Strategic Fund | 743,040 | 0 | 0 | 0 | For |
| Charles Schwab | 588,455 | 0 | 0 | 0 | For |
| TIAA | 415,114 | 0 | 0 | 0 | For |
| AllianceBernstein | 406,747 | 0 | 0 | 0 | For |
| Aberdeen | 406,700 | 0 | 0 | 0 | For |
| Principal | 304,878 | 0 | 0 | 0 | For |
| Equitable | 304,744 | 0 | 0 | 0 | For |
| ALGER FUNDS | 302,068 | 0 | 0 | 0 | For |
| Loomis Sayles | 280,157 | 0 | 0 | 0 | For |
| AB DISCOVERY GROWTH FUND, INC. | 239,130 | 0 | 0 | 0 | For |
| Hartford | 229,255 | 0 | 0 | 0 | For |
| Advantage Advisers Xanthus Fund, L.L.C. | 211,967 | 0 | 0 | 0 | For |
| MUTUAL FUND SERIES TRUST | 200,000 | 0 | 0 | 0 | For |
| Yiheng Capital Management, L.P. | 176,260 | 0 | 0 | 0 | For |
| Brighthouse | 159,055 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 153,335 | 0 | 0 | 0 | For |
| JPMorgan | 135,429 | 0 | 0 | 0 | For |
| Dimensional | 135,214 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 126,846 | 0 | 0 | 0 | For |
Showing the 25 largest of 80 asset managers. All 80 are in the interactive database (link above).
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported.
| # | Asset manager | Shares voted |
|---|---|---|
| 1 | Vanguard | 7,781,005 |
| 2 | T. Rowe Price | 3,360,888 |
| 3 | Fidelity | 2,614,174 |
| 4 | JANUS INVESTMENT FUND | 2,139,467 |
| 5 | BlackRock | 1,750,114 |
| 6 | State Street | 975,840 |
| 7 | ACAP Strategic Fund | 743,040 |
| 8 | Charles Schwab | 588,455 |
| 9 | TIAA | 415,114 |
| 10 | AllianceBernstein | 406,747 |
| # | Asset manager | Shares voted |
|---|---|---|
| 1 | RTW INVESTMENTS, LP | 7,419,340 |
| 2 | Janus Henderson | 6,535,723 |
| 3 | Wellington | 5,388,995 |
| 4 | T. Rowe Price | 4,459,375 |
| 5 | BlackRock | 2,445,355 |
| 6 | State Street | 2,401,865 |
| 7 | GEODE CAPITAL MANAGEMENT, LLC | 1,757,957 |
| 8 | MARSHALL WACE, LLP | 1,693,805 |
| 9 | Deep Track Capital, LP | 1,407,806 |
| 10 | AllianceBernstein | 1,160,904 |
Shown as share counts, not percentages: no shares-outstanding figure has been matched to AKERO THERAPEUTICS INC. for the 2024-2025 season, so there is no denominator to divide by.
At AKERO THERAPEUTICS INC.'s shareholder meeting held June 3, 2025, in the 2024-2025 proxy season, 258 asset managers reported votes on at least one of its 4 ballot items in their SEC Form N-PX filings, covering 1,326 separate fund positions. On the most widely held item on that ballot — To consider and act upon a non- binding, advisory vote to approve the compensation of our named… — FOR was 98% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: AKERO THERAPEUTICS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 4, 2025.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.
AKERO THERAPEUTICS INC. proxy season coverage: 2023-2024 · 2024-2025 (this page) · 2025-2026.
Proxy Votes Now, “AKERO THERAPEUTICS INC. 2025 Annual Meeting: Shareholder Vote Results”, https://proxyvotesnow.com/company/akero-therapeutics-inc/2025 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.